Skip to main content
Clinical Trials/NCT01659827
NCT01659827
Completed
Not Applicable

A Prospective, Randomized, Blinded, Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar Fasciitis

MiMedx Group, Inc.1 site in 1 country45 target enrollmentSeptember 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Plantar Fasciitis
Sponsor
MiMedx Group, Inc.
Enrollment
45
Locations
1
Primary Endpoint
Change from Baseline in American Orthopaedic Foot and Ankle Society (AOFAS) Hind Foot Score at 8 Weeks
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The purpose of this study is to determine whether the AmnioFix Injectable human amniotic membrane is effective in the treatment of recalcitrant plantar fasciitis.

Registry
clinicaltrials.gov
Start Date
September 2012
End Date
March 2013
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • At least 18 years old.
  • Both male and female patients will be selected.
  • Plantar fasciitis has been treated with conservative usual care for at least 8 weeks, including at least three of the following modalities
  • Corticosteroid injection
  • Stretching exercises
  • Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence).
  • Patient understands and is willing to participate in the clinical study and can comply with weekly visits and the follow-up regimen.
  • Patient has read and signed the IRB/IEC approved Informed Consent Form before screening procedures are undertaken.

Exclusion Criteria

  • Prior surgery at the site
  • Site that exhibits clinical signs and symptoms of infection
  • History of chronic plantar fasciitis of more than twelve months
  • Evidence of significant neurological disease of the feet
  • Non Ambulatory Patients
  • The presence of comorbidities that can be confused with or can exacerbate the condition including:
  • Calcaneal stress fracture
  • Nerve entrapment syndrome (baxter nerve syndrome or tarsal tunnel)
  • Plantar fascial rupture
  • Systemic disorders associated with enthesiopathy such as Gout, Reiters syndrome, rheumatoid arthritis, etc.

Outcomes

Primary Outcomes

Change from Baseline in American Orthopaedic Foot and Ankle Society (AOFAS) Hind Foot Score at 8 Weeks

Time Frame: 8 Weeks

Secondary Outcomes

  • Time to return to normal activities(Up to 8 Weeks)
  • Pain scale(Weekly up to 8 Weeks)

Study Sites (1)

Loading locations...

Similar Trials